


1653



Attorney Docket No.: 10081.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nørregard-Madsen et al.

Confirmation No: 9980

Serial No.: 09/976,414

Group Art Unit: 1653

Filed: October 12, 2001

Examiner: To be assigned

For: Subtilase Variants

TECH CENTER 1600/2900

RECEIVED
JUL 11 2002

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on July 2, 2002.

Julie Tabarovsky
(name of person mailing paper)

Julie Tabarovsky
(signature of person mailing paper)

#3
nb
07/15/02

PATENT



Attorney Docket No.: 10081.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Nørregard-Madsen et al.

Confirmation No: 9980

Serial No.: 09/976,414

Group Art Unit: 1653

Filed: October 12, 2001

Examiner: To be assigned

For: Subtilase Variants

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 02/21760
2. WO 01/44452


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or

b fore the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 2, 2002

A handwritten signature in cursive script, reading "Elias J. Lambiris", written over a horizontal line.

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No.
10081.200-US

Serial No.
09/976,414

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Nørregård-Madsen et al.

Filing Date
October 12, 2001

Group
1653

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

July 1, 2002

TECH CENTER 1800/232